Luke Albertson is the Co-founder and CEO of Brine Medical, bringing extensive entrepreneurial experience and leadership to the company. Luke has successfully founded and scaled multiple innovative ventures in the healthcare and education sectors.

Luke has successfully led teams in isolating and developing marine-derived compounds, resulting in several promising preclinical candidates for cancer and antibiotic-resistant infections. His strategic partnerships with institutions including Harvard University and Scripps Institution of Oceanography have enhanced Brine Medical’s research capabilities.

* Recently awarded the Harvard Dean Shinagel Exceptional Teaching Award

Julie Simpson is the Co-founder and Chief Scientist at Brine Medical, where she spearheads the scientific discovery and development of marine-derived pharmaceuticals. With over 15 years of experience in marine biology and a distinguished career in marine research, Julie is a leading expert in the field. She holds advanced degrees in Marine Biology and has led numerous pioneering marine exploration projects, from deep-sea expeditions to coral reef studies. Julie’s research has been instrumental in identifying unique bioactive compounds with significant therapeutic potential, resulting in multiple high-impact publications and patents.

Her innovative approach to marine bioprospecting and her ability to translate marine biodiversity into groundbreaking medical therapies are central to Brine Medical’s mission. Julie has forged strong collaborations with top-tier academic institutions and pharmaceutical companies, enhancing the company’s research capabilities and accelerating the development pipeline.

 * Patent-pending BRM-123 is a compound isolated from deep-sea sponges, which has shown potent anti-cancer properties in preclinical studies by inhibiting the growth of breast and pancreatic cancer cells.

Sympact Neeley is the Chief Scientist at Brine Medical, where she leads the compound isolation and analysis efforts. With over 20 years of experience in biochemistry and pharmaceutical research, Sympact is an expert in identifying and characterizing bioactive compounds from marine organisms. She holds a Ph.D. in Biochemistry and has developed innovative methodologies for extracting and analyzing natural products, particularly those with potential therapeutic applications.

At Brine Medical, Sympact’s leadership in compound isolation ensures that we harness the vast potential of marine biodiversity to develop novel therapies for oncology, infectious diseases, and dermatology. Her innovative approaches and dedication to scientific excellence drive our mission to transform marine bioresources into groundbreaking medical solutions.

* Sympact is the lead inventor on a patented method for isolating a potent antimicrobial compound from marine algae, known as MA-456. This compound has shown exceptional efficacy against multiple drug-resistant bacterial strains, representing a significant advancement in the fight against antibiotic resistance. The patent covers the extraction process, compound structure, and its application in treating bacterial infections.